The effect of PEGylation on the stability of small therapeutic proteins

Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST)

(2017) C. J. Sweeney et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

(2010) Roni Mamluk et al.   mAbs

The Impact of PEGylation on Biological Therapies

(2008) Francesco M Veronese et al.   BIODRUGS

Stabilization of α-chymotrypsin upon PEGylation correlates with reduced structural dynamics

(2008) José A. Rodríguez-Martínez et al.   BIOTECHNOLOGY AND BIOENGINEERING

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

(2008) Sean P Dineen et al.   BMC CANCER

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

(2008) Andrea Molckovsky et al.   Journal of Hematology & Oncology